The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.
| Revenue (TTM) | $4.23B |
| Gross Profit (TTM) | $2.77B |
| EBITDA | $886.40M |
| Operating Margin | -2.87% |
| Return on Equity | 2.85% |
| Return on Assets | 2.52% |
| Revenue/Share (TTM) | $21.49 |
| Book Value | $42.27 |
| Price-to-Book | 1.80 |
| Price-to-Sales (TTM) | 3.56 |
| EV/Revenue | 4.059 |
| EV/EBITDA | 19.29 |
| Quarterly Earnings Growth (YoY) | 26.90% |
| Quarterly Revenue Growth (YoY) | 7.90% |
| Shares Outstanding | $195.03M |
| Float | $193.68M |
| % Insiders | 0.61% |
| % Institutions | 109.24% |
Volatility is currently contracting
The Cooper Companies (COO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SAN RAMON, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report third quarter 2026 financial results on Wednesday, September 9, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.
SAN RAMON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, released today its 2025 Corporate Sustainability Report. The report showcases the company's commitment to people and planet, supported by expanded performance metrics and continued progress on sustainability priorities. A key milestone in this year's report is the company's first-time disclosure of Scope 3 greenhouse gas emissions, enhancing transparency and strengthening its sustainability reporting.
COO's premium lens, myopia control and fertility momentum support growth, but Asia-Pacific weakness and margin pressure keep the outlook measured.
COO's premium lenses, MiSight and fertility trends support growth, but Asia-Pacific softness, portfolio shifts and cost pressure keep execution in focus.
The Cooper Companies gets a hold rating for my initial coverage. Strengths are driven by the top line and market demand for contact lenses for a variety of eye conditions, with only a handful of key peers in this niche. Margin and ROE improvement remains a challenge, to improve metrics vs peers like Alcon, Bausch & Lomb, and Johson & Johnson, as well as competing on product innovation.
The Cooper Companies, Inc. remains a Hold as valuation nears attractive levels but litigation risk and mixed profitability warrant caution. Revenue growth is robust, particularly in the CooperVision segment, with strong performance in EMEA and the Americas offsetting Asia Pacific softness. Litigation charges from embryo culture media recalls have materially impacted reported profitability, but are not expected to alter COO's long-term outlook.
Evaluate The Cooper Companies' (COO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
The medical device maker gave an update on its troubled CooperSurgical business segment that was music to Wall Street's ears.
Cooper Companies NASDAQ: COO reported record revenue and non-GAAP earnings for its fiscal second quarter of 2026, while management said it is advancing discussions with multiple parties interested in CooperSurgical as part of its strategic review.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COO and any ticker you trade — then tracks every position and per-strategy win rate.
